A Disintegrin and Metalloproteinase with Thrombospondin Motifs (ADAMTS) is a family of zinc-dependent extracellular enzymes that play a crucial role in a myriad of biological processes. These enzymes are active participants in the cleavage, restructuring, and maintenance of the extracellular matrix (ECM), which is a vital component of tissues and organs. ADAMTS-19, like other members of the ADAMTS family, is involved in the proteolytic processing of various substrates within the ECM. Its signaling mechanisms are embedded within a web of regulatory pathways that include cytokine networks, growth factors, and other enzymes. These pathways modulate ADAMTS-19 expression levels and enzymatic activity, implicating it in ECM remodeling, cell migration, and the modulation of other cellular behaviors. Factors like epigenetic regulation, substrate availability, and endogenous inhibitors further add layers of complexity to the regulation of ADAMTS-19 activity.
ADAMTS-19 activators are aimed at understanding molecules that can specifically or indirectly modulate the activity of ADAMTS-19. While several types of molecules are being investigated for their role in activating or facilitating ADAMTS-19 function, these range from small organic compounds to larger biological molecules. Small molecules like HDAC inhibitors and TGF-β inhibitors have been researched for their impact on the epigenetic and transcriptional regulation of ADAMTS-19, respectively. Others like MMP inhibitors can indirectly contribute by preserving the availability of substrates in the ECM for ADAMTS-19. Activators may also interact with ADAMTS-19 through various mechanisms such as inhibition of opposing pathways or through complex signaling cascades. These molecules provide valuable insights into the intricate layers of regulation governing ADAMTS-19 activity.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $133.00 $275.00 | 37 | |
HDAC Inhibitors may influence the epigenetic regulation of ADAMTS-19 gene expression. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $82.00 $216.00 $416.00 | 48 | |
By inhibiting TGF-β, these could potentially upregulate ADAMTS-19 expression if TGF-β is a suppressor. | ||||||
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
DNA Methyltransferase Inhibitors could affect the methylation status of the ADAMTS-19 gene, potentially increasing its expression. | ||||||
N-Acetyl-L-cysteine | 616-91-1 | sc-202232 sc-202232A sc-202232C sc-202232B | 5 g 25 g 1 kg 100 g | $34.00 $74.00 $270.00 $114.00 | 34 | |
May activate ADAMTS-19 by reducing oxidative stress conditions that otherwise inhibit it. | ||||||
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $62.00 $85.00 $356.00 | 155 | |
NF-κB Inhibitors could potentially upregulate ADAMTS-19 by suppressing NF-κB signaling, if NF-κB acts as a suppressor. | ||||||
XAV939 | 284028-89-3 | sc-296704 sc-296704A sc-296704B | 1 mg 5 mg 50 mg | $36.00 $117.00 $525.00 | 26 | |
Wnt Pathway Inhibitors may influence ADAMTS-19 by affecting Wnt signaling, which is known to be involved in ECM remodeling. | ||||||
Gö 6983 | 133053-19-7 | sc-203432 sc-203432A sc-203432B | 1 mg 5 mg 10 mg | $105.00 $299.00 $474.00 | 15 | |
PKC Inhibitors could influence various signaling pathways that may indirectly activate ADAMTS-19. | ||||||
Ruxolitinib | 941678-49-5 | sc-364729 sc-364729A sc-364729A-CW | 5 mg 25 mg 25 mg | $251.00 $500.00 $547.00 | 16 | |
JAK/STAT Inhibitors may affect the cytokine signaling that influences ADAMTS-19 expression or activity. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $114.00 $166.00 $947.00 | 19 | |
MEK Inhibitors could affect MAPK pathways that influence ADAMTS-19. | ||||||
Cobalt(II) chloride | 7646-79-9 | sc-252623 sc-252623A | 5 g 100 g | $64.00 $176.00 | 7 | |
HIF-1α Stabilizers could potentially influence the hypoxia-related activation or expression of ADAMTS-19. | ||||||